Objective To evaluate the clinical value of 9 9 Tc m-HL91 as a tumor positive imaging agent in diagnosis of pulmonary neopl asms. Methods We performed 2 h,4 h planar and 4 h tomogr aphy fusion imaging after injection of HL91 on 42 patients with high probability of pulmonary cancer. Tumor-to-normal tissue background (T/N) ratios were meas ured for all scans. Results T/N ratios at 2 h,4 h planar and 4 h transectional imaging in malignant group were 1.50? 0.17 ,1.71?0.22 and 2.72?0.75, respectively; while in benign group, they were 1.21?0.10,1.25 ?0.22 and 1.49?0.36, respectively. 4 h delay T/N ratios in malignant group we re obviously higher than 2 h ( P 0.05). There were no remarkable differences of T/N ra tios in different phases and histological types of lung carcinoma. Using maligna nt transection ratio ( -1s ) as diagnostic threshold, the sensitivity , specificity and accuracy were 84.85% , 88.89% and 85.71% , respectiv ely. Using transection ratio( +1s ) of benign group as diagnostic th reshold , the sensitivity, specificity and accuracy were 90.91%, 88.89% and 95.2 4%,respectively. Conclusion The results indicate that as a tumor positive imaging agent 99 Tc m-HL91 is useful in diagosising pulmon ary neoplasms.

Objective To certify whether 99mTc-HL91 can be trapped in ischemic myocardium prominently for clinical imaging. Methods The model of myocardial ischemia in rabbits was prepared and the distribution of 99mTc-HL91 was observed. The distribution of 99mTc-HL91 in the whole body was also observed. Results The myocardium of the left ventricle supplied by LCX was ischemic according to the change of electrical physiology and the results of NBT dying. The radioactivity in the myocardium of left ventricle supplied by LCX was higher than that supplied by LAD. LCX/LAD: 120 min, 2.57; 180 min, 3.45. 99mTc-HL91 was mostly distributed in the liver and kidney, next, the stomach and intestine. It was excreted through urination and defecation. There was little radioactivity in the heart and lungs and it eliminated quickly. 99mTc-HL91 was eliminated quickly from blood, too. Conclusion Ischemic myocardium can trap 99mTc-HL91 more significantly and relatively prominently at 180 minutes of post-injection. 99mTc-HL91 can be used in myocardial hypoxia imaging.